WO2018143574A1 - Composition de diagnostic de l'obésité et son utilisation - Google Patents

Composition de diagnostic de l'obésité et son utilisation Download PDF

Info

Publication number
WO2018143574A1
WO2018143574A1 PCT/KR2018/000423 KR2018000423W WO2018143574A1 WO 2018143574 A1 WO2018143574 A1 WO 2018143574A1 KR 2018000423 W KR2018000423 W KR 2018000423W WO 2018143574 A1 WO2018143574 A1 WO 2018143574A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
mrna
obesity
measuring
accession number
Prior art date
Application number
PCT/KR2018/000423
Other languages
English (en)
Korean (ko)
Inventor
최명숙
류리
조수정
최지영
Original Assignee
경북대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경북대학교 산학협력단 filed Critical 경북대학교 산학협력단
Publication of WO2018143574A1 publication Critical patent/WO2018143574A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Definitions

  • the agent for measuring the protein level may be an antibody that specifically binds to the protein encoded by the gene.
  • the method may further comprise the step of measuring the mRNA level of the PPHLN1 gene or the protein encoded by the gene.
  • test substance may be selected from the group consisting of compounds, microbial cultures or extracts, natural product extracts, nucleic acids, and peptides.
  • the present invention also provides a kit for diagnosing obesity comprising the composition.
  • the biological sample derived from the subject may include tissue, cells, whole blood, blood, saliva, sputum, cerebrospinal fluid and urine, more preferably blood, and more preferably peripheral blood mononuclear cells in blood. May be, but is not limited to this.
  • the present invention comprises the steps of treating a test substance to a cell expressing the RAB6A gene; Measuring the expression level of the gene in the cell; And it provides a screening method of the obesity treatment substance comprising the step of comparing the expression level of the gene compared to the control group not treated test substance.
  • the gene includes a gene whose expression is changed in the obese group through one embodiment of the present invention, and increases the expression of the gene whose expression is decreased in the obese group by comparing the expression level of the gene after treatment with the test substance with the normal control group.
  • a test substance that reduces the expression of a gene with increased expression in the obese group may be selected as a therapeutic agent for obesity.
  • the produced sequences were FastQC v0.10.0 for quality check, aligned with genome sequences using Tophat V.1.3.3, and the referenced genome was sequenced by Homo sapiens (hg19).
  • Gene expression levels were calculated using Cufflinks v.2.0.2.
  • the extracted genes were subjected to normalization and extracted genes with significantly changed expression (p value of ⁇ 0.05 and fold change of> 1.5).
  • the present invention relates to a composition for diagnosing obesity and its use, by confirming the increased expression of RAB6A and PPHLN1 genes in the peripheral blood mononuclear cells and visceral fat of the obese group, the RAB6A and PPHLN1 genes prevent and treat obesity and related complications It is expected to be useful as a biomarker for diagnosis and drug response diagnosis, targets of therapeutic substances and screening for the development of therapeutic substances.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition de diagnostic de l'obésité et son utilisation et, plus précisément, une composition de diagnostic de l'obésité, contenant une préparation de mesure de la teneur en ARNm ou en protéine des gènes (RAB6A) et (PPHLN1) dont l'expression est modifiée chez les personnes obèses par comparaison aux personnes normales ; un procédé fournissant des informations pour le diagnostic ; et un procédé de criblage d'un matériau de traitement de l'obésité. Selon la présente invention, les gènes, dont l'expression était modifiée dans un groupe d'obèses, peuvent être utilisés comme biomarqueurs importants pour le diagnostic de réaction au médicament et pour le diagnostic de prévention et de traitement de l'obésité et des complications qui lui sont associées, et peuvent être également utiles comme biomarqueurs pour cibler et développer un matériau de prévention ou de traitement de l'obésité et des complications qui lui sont associées.
PCT/KR2018/000423 2017-02-02 2018-01-09 Composition de diagnostic de l'obésité et son utilisation WO2018143574A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170014889A KR101745297B1 (ko) 2017-02-02 2017-02-02 비만 진단용 조성물 및 이의 용도
KR10-2017-0014889 2017-02-02

Publications (1)

Publication Number Publication Date
WO2018143574A1 true WO2018143574A1 (fr) 2018-08-09

Family

ID=59219848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/000423 WO2018143574A1 (fr) 2017-02-02 2018-01-09 Composition de diagnostic de l'obésité et son utilisation

Country Status (2)

Country Link
KR (1) KR101745297B1 (fr)
WO (1) WO2018143574A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101745297B1 (ko) * 2017-02-02 2017-06-09 경북대학교 산학협력단 비만 진단용 조성물 및 이의 용도
KR101968962B1 (ko) 2017-08-23 2019-04-15 세종대학교산학협력단 비만 저항성 진단용 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1512752A1 (fr) * 2003-09-08 2005-03-09 Centre National De La Recherche Scientifique (Cnrs) Méthode diagnostique d'obésité
US20080085516A1 (en) * 2002-09-03 2008-04-10 Myriad Genetics, Incorporated Obesity gene and use thereof
KR20140125553A (ko) * 2013-04-19 2014-10-29 경북대학교 산학협력단 비만 진단용 조성물
US20150218522A1 (en) * 2013-06-11 2015-08-06 President And Fellows Of Harvard College Sc-beta cells and compositions and methods for generating the same
KR101594735B1 (ko) * 2015-08-13 2016-02-17 경북대학교 산학협력단 비만 조기진단용 조성물 및 이의 용도
KR101620274B1 (ko) * 2015-08-11 2016-05-11 경북대학교 산학협력단 비만의 진단용 조성물 및 이의 용도
KR101745297B1 (ko) * 2017-02-02 2017-06-09 경북대학교 산학협력단 비만 진단용 조성물 및 이의 용도

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080085516A1 (en) * 2002-09-03 2008-04-10 Myriad Genetics, Incorporated Obesity gene and use thereof
EP1512752A1 (fr) * 2003-09-08 2005-03-09 Centre National De La Recherche Scientifique (Cnrs) Méthode diagnostique d'obésité
KR20140125553A (ko) * 2013-04-19 2014-10-29 경북대학교 산학협력단 비만 진단용 조성물
US20150218522A1 (en) * 2013-06-11 2015-08-06 President And Fellows Of Harvard College Sc-beta cells and compositions and methods for generating the same
KR101620274B1 (ko) * 2015-08-11 2016-05-11 경북대학교 산학협력단 비만의 진단용 조성물 및 이의 용도
KR101594735B1 (ko) * 2015-08-13 2016-02-17 경북대학교 산학협력단 비만 조기진단용 조성물 및 이의 용도
KR101745297B1 (ko) * 2017-02-02 2017-06-09 경북대학교 산학협력단 비만 진단용 조성물 및 이의 용도

Also Published As

Publication number Publication date
KR101745297B1 (ko) 2017-06-09

Similar Documents

Publication Publication Date Title
US20220162703A1 (en) Methods of diagnosing inflammatory bowel disease through rnaset2
AU2017293417B2 (en) Biomarkers for inflammatory bowel disease
US9951387B2 (en) Methods for detection of depressive disorders
KR20200002241A (ko) 비만 진단을 위한 마이크로RNA-26b 또는 마이크로RNA-4449 바이오마커 및 이의 용도
WO2016137242A1 (fr) Biomarqueur de l'arthrite dégénérative et kit d'analyse diagnostique ou pronostique de l'arthrite dégénérative comprenant ledit biomarqueur
WO2018143574A1 (fr) Composition de diagnostic de l'obésité et son utilisation
US20140308241A1 (en) Biomarkers for t cell malignancies and uses thereof
Akutsu et al. Development of a multiplex RT-PCR assay and statistical evaluation of its use in forensic identification of vaginal fluid
CN106222243B (zh) 一种用于精神分裂症诊断的circRNA标志物、试剂盒及基因芯片
WO2017026691A1 (fr) Composition pour le diagnostic de l'obésité et ses utilisations
EP2603604B1 (fr) Procédé et kit pour le diagnostic et le pronostic de la tolérance dans la greffe de foie au moyen de tissus hépatiques
CN107227358A (zh) Numb在绝经后妇女原发性骨质疏松症诊断或预后中的用途
WO2017026692A1 (fr) Composition pour le diagnostic précoce de l'obésité et son utilisation
KR102384992B1 (ko) 대장암 환자의 연령 특이적 바이오마커 및 이의 용도
US10890579B2 (en) Methods and kits for detecting a fusion messenger RNA transcript or a polypeptide encoded by the fusion messenger RNA transcript
Chen et al. Functional characterization of DLK1/MEG3 locus on chromosome 14q32. 2 reveals the differentiation of pituitary neuroendocrine tumors
WO2016195415A1 (fr) Utilisation de sh3yl1 en tant que marqueur pour le diagnostic d'une néphropathie
WO2016200120A1 (fr) Gène associé à la sensibilité à l'ibrutinib chez les patients atteints de glioblastome, et utilisation de ce dernier
WO2023008673A1 (fr) Marqueur complexe basé sur l'apprentissage automatique permettant de déterminer la stéatohépatite non alcoolique et son utilisation
WO2017142219A1 (fr) Composition pour diagnostiquer une leucémie au moyen du gène tmem57 ou nudc
RU2719411C1 (ru) Способ определения предрасположенности к нарушению репродуктивной функции у женщин в условиях избыточной контаминации фенолом
WO2022075774A1 (fr) Biomarqueur pour prévoir une métastase de cancer du pancréas et utilisation associée
KR20180099123A (ko) 항암제에 대한 저항성 예측용 바이오마커
US9988681B2 (en) Diagnosis and prognosis of severity of autism spectrum disorders
WO2022098619A1 (fr) Compositions et procédés pour améliorer une thérapie cancéreuse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18747971

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18747971

Country of ref document: EP

Kind code of ref document: A1